Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has engaged IBN to assist with its corporate communications strategy, according to a press release. The move is intended to generate greater awareness of the clinical-stage biopharmaceutical company and of MindWave Innovations Inc., its wholly owned subsidiary developing institutional digital asset infrastructure. The arrangement places two distinct corporate stories — drug development and digital asset infrastructure — under a single communications umbrella.

Through the engagement, IBN will deploy its investor-focused distribution network — including more than 5,000 syndication outlets, newsletters, social media channels, InvestorWire and other outreach tools — to increase visibility for Apimeds. The full press release can be viewed at

Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid, biologic-based therapies for pain management — a designation describing a company whose therapies are still in development. Additional information is available at www.ApimedsUS.com.

MindWave Innovations Inc. is developing enterprise blockchain infrastructure and institutional technology platforms through its MindChain ecosystem, which spans four verticals:

• InsurTech through BlockAssure, which is developing a Bermuda-framework platform applying Bitcoin reserves as regulatory capital to support life and property and casualty underwriting;
• ClimateTech through AQUAE and the ALCI index, which measure, verify and tokenize ecosystem services into institutional-grade assets;
• HealthTech through the Apitox development program; and
• RWA Tech through Nexus Global Partners, bringing institutional real estate on-chain within a compliance-first, insurance-enhanced framework.

According to the announcement, the engagement is intended to raise investor awareness of Apimeds' dual focus: its biopharmaceutical operations and its subsidiary's digital asset infrastructure. Of the four verticals, HealthTech — carried through the Apitox development program — is the arm of MindChain that sits closest to the parent company's pharmaceutical side. MindWave's MindChain ecosystem combines insured custody, transparent reporting and technology-driven portfolio management to support risk-aware yield on Bitcoin reserves and institutional participation in the digital asset economy — a profile that could attract investors interested in both healthcare and blockchain technology.

MissionIR, the communications platform issuing the release, specializes in assisting investor relations firms with syndicated content that enhances the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which delivers access to wire solutions via InvestorWire, article and editorial syndication to more than 5,000 outlets, enhanced press release distribution, social media reach across millions of followers, and a full suite of tailored corporate communications solutions. Further information is available at www.MissionIR.com.

The latest news and updates relating to APUS are available in the company's newsroom at Readers following the story can track further updates through the original release and the company newsroom.

The collaboration underscores the growing intersection between traditional biopharmaceutical companies and emerging digital asset technologies, potentially positioning Apimeds to appeal to a broader investor base.

This article first appeared on citybuzz.